// App-Quantinova.ai

102 : High Rates of Durable Complete Response in ALL, NHL, and CLL After Immunotherapy with Optimized Lymphodepletion and Defined Composition CD19 CAR-T cells (JCAR014)

Researchers

Presenter

  • Cameron John Turtle

Principal Investigators

  • Laila-Aicha Hanafi

  • Carolina Berger

  • Theodore Gooley

  • Colette Chaney

  • Sindhu Cherian

  • Lori Soma

  • Xueyan Chen

  • Cecilia CS Yeung

  • Keith Loeb

  • Brent L. Wood

  • Michael Hudecek

  • Daniel Sommermeyer

  • Daniel Li

  • Kevin Anthony Hay

  • Shelly Heimfeld

  • Stanley R. Riddell

  • David G. Maloney

Medical Centers

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Department of Laboratory Medicine, University of Washington, Seattle, WA

  • University of Washington, Seattle, WA

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Department of Medicine II, University of Wuerzburg, Wuerzburg, Germany

  • Juno Therapeutics, Seattle, WA

  • The University of British Columbia, Vancouver, BC, Canada

Locations

  • United States

  • Germany

  • Canada

Companies

  • Juno Therapeutics, I

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Lymphocytopenia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • Lymphocyte count

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT01865617

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved